Industry Veteran Anil Kumar Matai Appointed as Independent Director of Jagsonpal Pharmaceuticals

Industry Veteran Anil Kumar Matai Appointed as Independent Director of Jagsonpal Pharmaceuticals​

Gurugram, India | June 25, 2026 – Jagsonpal Pharmaceuticals Ltd has announced the appointment of Mr. Anil Kumar Matai as an Independent Director to the Company's Board, effective June 25, 2026, pending shareholder approval.

Mr. Matai joins the board bringing extensive leadership experience across the pharmaceutical and healthcare sectors. He possesses more than three decades of distinguished career experience, having held senior leadership positions where he was instrumental in driving strategic growth, operational excellence, and business transformation within the industry.

Manish Gupta, Managing Director of Jagsonpal Pharmaceuticals Ltd., commented on the appointment, stating: "We are delighted to welcome Mr. Anil Kumar Matai to the Jagsonpal family. With his rich experience and deep understanding of the pharmaceutical and healthcare industry, Mr. Matai brings valuable input that will be instrumental as we continue to scale our business and pursue new growth opportunities."

Regarding the role, Mr. Anil Kumar Matai said: "I am delighted to join the Board of Jagsonpal Pharmaceuticals and look forward to collaborating with the Board and management team. I hope to leverage my experience and understanding of the pharmaceutical industry to contribute to the Company's growth, strengthen performance and create value for all stakeholders."

Company Profile​

Jagsonpal Pharmaceuticals Limited is noted as a leading pharmaceutical company in the Indian market, boasting a proven track record spanning over four decades. The company maintains a robust portfolio that covers Gynaecology, Orthopaedics, Dermatology, and Child-care segments.

Through its dedicated efforts, Jagsonpal has successfully developed multiple brands that hold market-leading positions within their respective segments. The company has established a strong niche through its 20+ brands among the Top 5 in the molecule category, coupled with an extensive pan-India presence maintained by a sales team of over 1000 professionals.

Jagsonpal Pharmaceuticals is listed on both the National Stock Exchange Limited (JAGSNPHARM) and Bombay Stock Exchange (Scrip code: 507789).

JAGSNPHARM Stock Price Movement​

Jagsonpal Pharmaceuticals Limited's stock slipped by 3.01% on Thursday, settling at ₹223.50 after shedding ₹6.91 from the previous close. The company traded a volume of 196,360 shares, maintaining an intraday range between a low of ₹219.87 and a high of ₹235.35.